Insights into the involvement of long non-coding RNAs in doxorubicin resistance of cancer

Frontiers in Pharmacology

Pharmacology

Guo-Ying Fang¹  Hai-Bo Zhang¹  Ying Zeng²  Jun-Li Deng³  Yang Hu⁴ 

[1] Department of Pharmacy, Hangzhou Women’s Hospital (Hangzhou Maternity and Child Health Care Hospital), Hangzhou, China;Department of Pharmacy, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, China;Department of Pharmacy, Zhujiang Hospital, Southern Medical University, Guangzhou, China;Guangzhou Institute of Respiratory Disease and China State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China;

关键词: long non-coding RNA;    doxorubicin;    drug resistance;    cancer;    molecular mechanisms;   

DOI  :  10.3389/fphar.2023.1243934

 received in 2023-06-21, accepted in 2023-08-31,  发布年份 2023

来源: Frontiers

【 摘 要 】

Doxorubicin is one of the most classical chemotherapeutic drugs for the treatment of cancer. However, resistance to the cytotoxic effects of doxorubicin in tumor cells remains a major obstacle. Aberrant expression of long non-coding RNAs (lncRNAs) has been associated with tumorigenesis and development via regulation of chromatin remodeling, transcription, and post-transcriptional processing. Emerging studies have also revealed that dysregulation of lncRNAs mediates the development of drug resistance through multiple molecules and pathways. In this review, we focus on the role and mechanism of lncRNAs in the progress of doxorubicin resistance in various cancers, which mainly include cellular drug transport, cell cycle disorder, anti-apoptosis, epithelial-mesenchymal transition, cancer stem cells, autophagy, tumor microenvironment, metabolic reprogramming and signaling pathways. This review is aimed to provide potential therapeutic targets for future cancer therapy, especially for the reversal of chemoresistance.

【 授权许可】

Unknown   
Copyright © 2023 Zhang, Hu, Deng, Fang and Zeng.